Dr Reddys Laboratories (RDY) Notes Payables (2009 - 2026)

Dr Reddys Laboratories (RDY) has reported Notes Payables for 9 consecutive years, with $630.0 million the latest figure, recorded in Q1 2026.

• Quarterly Notes Payables rose 41.57% year-over-year to $630.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $630.0 million (up 41.57% YoY) and the FY2026 annual result came in at $630.0 million, up 41.57% from the prior year.
• Notes Payables improved to $630.0 million in Q1 2026 per RDY's latest filing, from $445.0 million in the prior quarter.
• Over the last five years, Notes Payables for RDY reached as high as $630.0 million in Q1 2026 and fell as low as $90.0 million in Q1 2023.
• A 5-year average of $335.0 million and a median of $357.0 million in 2022 frame the typical range for Notes Payables.
• Annual changes were most pronounced in 2023 — Notes Payables plunged 74.79% — and 2025, when it soared 190.85%.
• Year by year, Notes Payables stood at $357.0 million in 2022, then tumbled by 74.79% to $90.0 million in 2023, then surged by 70.0% to $153.0 million in 2024, then soared by 190.85% to $445.0 million in 2025, then soared by 41.57% to $630.0 million in 2026.
• According to Business Quant data, Notes Payables over the past three periods registered $630.0 million, $445.0 million, and $153.0 million for Q1 2026, Q1 2025, and Q1 2024 respectively.